- Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?2017 | Faculty of Medicine in Pilsen
- Do metastases in the brain in a tumor with ALK translocation always mean ineffectiveness of crizotinib therapy?2017 | Faculty of Medicine in Pilsen
- Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- First experience on crizotinib therapy in non small cell lung cancer patient with EML-4 ALK translocation in Czech republic2012 | Faculty of Medicine in Pilsen
- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- Crizotinib - multitargeted inhibitor in targeted NSCLC therapyPublication without faculty affiliation
- Interdisciplinary consensus for predictive investigations in non-small cell lung cancer (NSCLC) - update 20122012 | Central Library of Charles University, Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Strategy of treatment in metastatic non-small cell lung cancer with driver mutations2016 | Faculty of Medicine in Pilsen
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia 20122014 | Faculty of Medicine in Pilsen
- Profile of the drug Xalkori2014 | Faculty of Medicine in Pilsen
- Case reports of patients with ALK-positive NSCLC and brain metastases2023 | First Faculty of Medicine
- ROS1 - another potencional target of our patients2014 | Faculty of Medicine in Pilsen
- Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)2022 | First Faculty of Medicine
- Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib2016 | Faculty of Medicine in Pilsen
- Two years longer and peaceful life thanks to alectinib2022 | Central Library of Charles University, Third Faculty of Medicine
- Targeted therapy of non-small cell lung cancer2021 | Faculty of Medicine in Pilsen
- What approach to ALK-positive NSCLC?2020 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Current procedures and news in the treatment of lung cancer2021 | First Faculty of Medicine
- Molecular Screening in ALK-Positive Anaplastic Large Cell Lymphoma: ALK Analysis, NGS Fusion Gene Detection, and T-cell Receptor Immunoprofiling2024 | Second Faculty of Medicine, Third Faculty of Medicine
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial2019 | Second Faculty of Medicine